Evidence map›Paper›PMID 41247072›Full record

ArticlemBio2025

SERINC5 co-expressed with HIV-1 Env or present in a target membrane destabilizes small fusion pores leading to their collapse.

Ruben M Markosyan, Mariana Marin, Gregory B Melikyan

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ruben M MarkosyanDepartment of Physiology and Biophysics, Rush University Medical Center, Chicago, Illinois, USA.
Mariana MarinDepartment of Pediatrics, Emory University, Atlanta, Georgia, USA.
Gregory B MelikyanDepartment of Pediatrics, Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-5385-3013

Funding

Biophysics of Protein-Mediated Membrane FusionR37AI150453 · NIAID · EMORY UNIVERSITY · PI Gregory B Melikian · 2020 to 2026
$4.1M
NIAID NIH HHS R37 AI150453NIH HHS R37 AI150453
6 · The paper itself

Abstract

Serine incorporator protein 5 (SERINC5) is a multipass membrane protein that reduces infectivity of retroviruses and other enveloped viruses through incorporating into budding virions and inhibiting their ability to fuse with target cells. Several mechanisms for anti-HIV activity of SERINC5 have been reported, including binding to Env glycoprotein, induction of conformational changes and destabilization of Env, as well as disruption of transmembrane asymmetry of viral envelope. All these reported anti-HIV mechanisms involve SERINC5 incorporation into progeny virions, while there is very little information regarding a potential antiviral activity of SERINC5 in target cells. Here, we show that SERINC5 expressed in target cells efficiently inhibits fusion with cells expressing Env glycoproteins of sensitive but not SERINC5-resistant HIV-1 strains. This activity of SERINC5 does not result from downregulation of CD4 or co-receptors on target cells or interference with the formation of prefusion Env/CD4/co-receptor complexes. We further demonstrate that SERINC5 destabilizes small fusion pores, causing their collapse, and that this block can be rescued by incorporation of phosphatidylserine into the plasma membrane of either effector (Env-expressing) or target cells. Interestingly, we did not detect a significant reduction in HIV-1 pseudovirus fusion with SERINC5-expressing target cells, while virus-mediated cell-cell fusion (fusion from without) was inhibited, suggesting a potential role of the virus's entry pathway in sensitivity to SERINC5 restriction. Collectively, our results reveal a novel mechanism of inhibition of HIV-1 fusion by SERINC5 through destabilization of small fusion pores in a manner that depends on lipid composition.IMPORTANCESERINC5 incorporates into virions produced by infected cells and inhibits HIV-1 fusion with target cells through a poorly understood mechanism. Here, we show that SERINC5 blocks HIV-1 Env-mediated cell fusion when expressed in either effector (Env-expressing) or target cells. Inhibition of Env-mediated fusion by SERINC5 expressed in target cells is not through reduction in receptor or co-receptor expression or interference with Env's ability to engage a requisite number of receptors and co-receptors. We demonstrate that the block of fusion is at a post-hemifusion stage of small fusion pores that collapse when SERINC5 is present in effector or target membrane and that this block is rescued by incorporation of specific anionic lipids, such as phosphatidylserine. These findings reveal a previously unappreciated mode of HIV-1 restriction through destabilization of small fusion pores that occurs irrespective of SERINC5 localization in either fusing membranes.

Indexed as

env Gene Products, Human Immunodeficiency VirusHIV-1Membrane ProteinsVirus InternalizationCell LineCell MembraneHEK293 CellsHIV InfectionsHumansenv Gene Products, Human Immunodeficiency VirusMembrane ProteinsSERINC5 protein, humancell-cell fusionfusion from withoutfusion porehemifusionHIV-1 envelopeHIV fusion inhibitorphosphatidylserineSERINC5

Identifiers

PMID41247072
PMCPMC12697135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.